ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript
ResMed Inc. ( RMD ) Q1 2026 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Brett Sandercock - Chief Financial Officer Conference Call Participants Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Laura Sutcliffe - Citigroup Inc. Exchange Research Saul Hadassin - Barrenjoey Markets Pty Limited, Research Division Lyanne Harrison - BofA Securities, Research Division Steven Wheen - Jarden Limited, Research Division David Bailey - Morgan Stanley, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Dan Hurren - MST Financial Services Pty Limited, Research Division Presentation Operator Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin.
Compared to Estimates, ResMed (RMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ResMed (RMD) Q1 Earnings and Revenues Beat Estimates
ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago.
Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q4 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brett A. Sandercock - Chief Financial Officer Michael J.
Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.08 per share a year ago.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
